In the UK, NICE guidance (TA875) recommends semaglutide only within specialist weight management services for specific patient groups
aureus have been previously described 30,31
However, if you frequently take doses early or if you accidentally took two doses within a short window (such as within 3 days), you should contact your prescribing physician or pharmacist for guidance on your next scheduled injection
[12] Currently licensed options in the UK include orlistat and semaglutide 2.4 mg (Wegovy) , the latter recommended by NICE technology appraisal TA875 for use within specialist weight management services in eligible adults
Regional Analysis North America Leading the GLP-1 Receptor Agonist Market North America accounted for the largest revenue share of 49.7% , supported by the high prevalence of type 2 diabetes and obesity, a developed healthcare system, and favorable reimbursement structures